<DOC>
	<DOCNO>NCT00300807</DOCNO>
	<brief_summary>1 . Evaluate safety , tolerability , virologic activity escalate single ( multiple ) dose XTL6865 , mixture ( 1:1 ) two human monoclonal antibody ( HCV-AbXTL68 HCV-AbXTL65 ) , patient chronic hepatitis C virus infection . 2 . Assess pharmacokinetics XTL6865 presence absence viral infection .</brief_summary>
	<brief_title>Study XTL6865 Patients With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description>The purpose study evaluate safety , tolerability , virologic activity escalate single multiple dos XTL6865 , mixture ( 1:1 ) two human monoclonal antibody ( HCV-AbXTL68 HCV-AbXTL65 ) , patient chronic hepatitis C virus infection . An additional purpose study ass pharmacokinetics XTL6865 presence absence viral infection . This study randomize , double blind , placebo-controlled , multi-center design ascend single dos patient chronic hepatitis C virus ( HCV ) infection . In addition Placebo , follow XTL6865 dos administer : 5 mg , 20 mg , 75 mg , 250 mg , 600 mg , 1200 mg , 2400 mg. No patient enrol one dose level . At dose level , 3 patient receive XTL6865 1 patient receive Placebo . After single dose infusion , patient follow 6 week . If certain criterion meet safety review 1200 mg dose cohort data determines XTL6865 safely administer tolerate dose level , patient 600 mg 1200 mg dose level eligible multiple dose phase . Infusions 600 mg give 4 eligible patient , one infusion per day , 5 day . One patient receive Placebo 3 patient receive XTL6865 600 mg . The patient follow 6 additional week . If certain criterion meet , 2400 mg dose cohort infuse . After safety review determine XTL6865 safely administer tolerated , patient 1200 mg 2400 mg dose level eligible multiple dose phase . Infusions 1200 mg give 4 eligible patient , one infusion per day , 5 day . One patient receive Placebo 3 patient receive XTL6865 1200 mg . The patient follow 6 additional week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>1. male female patient 18 65 year age ; 2. female patient must either postmenopausal , surgically sterile , nonpregnant nonlactating negative serum pregnancy test result prior enrollment study . Female patient childbearing potential ( include perimenopausal woman menstrual period within 1 year ) must use appropriate birth control entire duration study . Male patient may either surgically sterile , abstinent , utilizing barrier contraceptive method . Abstinence contraceptive regimen must maintain screening , treatment period 6 week follow XTL6865 dose ; 3. patient persistently HCV RNApositive remain HCV RNApositive screening ( patient must HCV RNAconcentrations least 2 log assay cutoff 600 IU/mL ) HCV antibody ( antiHCV ) positive ; 4. patient negative human immunodeficiency virus ( HIV ) , hepatitis delta virus ( HDV ) , evidence chronic hepatitis B virus ( HBV ) infection ( assessed Hepatitis B surface antigen HBV DNA blood within 3 month Day 1 study ) clinical sign , symptom , laboratory abnormality ( e.g . amino transferase ) lead diagnosis current acute Hepatitis B disease ; 5. patient reasonably good health , determine Investigator base medical history , physical examination , vital sign , electrocardiogram ( ECG ) , clinical laboratory test , except finding relate hepatitis C positive status . 6. subject ’ private physician inform subject ’ plan participation study ; 7. capable understand comply protocol , willing reside study unit study period cooperate fully Investigator site personnel , must sign informed consent document prior performance studyrelated procedure ; 8. infect HCV genotype 1 9. fail previous treatment HCV infection approve regimen IFN/RBV pegylated IFN/RBV . Treatment failure include nonresponse ( defined patient experience &gt; 2 log decrease HCV RNA 12 week treatment fail clear virus limit detection 24 week treatment ) relapse ( define reemergence detectable concentration HCV RNA response treatment ) . Treatment must discontinue least 3 month prior Day 1 study . 1. liver transplant patient ; 2. patient diabetes HbA1c screen 7 % ; 3. patient previously receive HCVAbXTL68 ; 4. woman pregnant , lactating , positive serum pregnancy test screen positive urine pregnancy test Day 1 checkin ; 5. patient hemoglobin &lt; 11 g/dL woman 12 g/dL men , platelet count &lt; 50,000 cells/mm3 , bilirubin &gt; 3 mg/dL , serum creatinine &gt; 1.5 x normal , INR &gt; 1.5 x normal , ALT &gt; 5 x upper limit normal , serum albumin &lt; 3.0 g/dL ( screen ) ; 6. patient history evidence advance decompensated liver disease , ascites , encephalopathy , bleed esophageal varix , hematuria proteinuria , alcohol intravenous drug abuse ( within &lt; = 1 year ) , fulminant liver failure , acute hepatitis source , periarteritis nodosa , serum sickness , acute infectious illness , severe psychiatric disorder ( include major depression ) , organic brain disorder , mental retardation , clinical condition diseases judgment Investigator would interfere study confound result ; 7. patient present active malignancy ( except superficial cancer ) 8. past history pulmonary embolus , deep vein thrombosis , current therapy heparin warfarin ; 9. patient history pulmonary hypertension ; 10. patient hypertension , investigator 's opinion , adequately control medication ( DBP &gt; 90 SBP &gt; 140 ) . In order ass PK fast state , patient able delay administration prescribe antihypertensive medicine several hour without anticipate undue risk medically significant increase blood pressure . Patient stable antihypertensive regime least 30 day prior screen change antihypertensive medication . 11. patient currently receive antiviral therapy HCV ; 12. patient receive IFN/RBV pegylated IFN/RBV treatment within 3 month study entry ( Day 1 ) ; 13. immunomodulatory therapy ( eg , systemic corticosteroid interferon ) within 3 month study entry ( Day 1 ) ; 14. patient meet condition prior concomitant treatment describe Section 6.6 protocol ; 15. patient consider schedule undergo surgical procedure study ; 16. take investigational drug 30 day prior screen visit ; 17. donate lose unit blood within 30 day prior screen visit ; 18. condition ( ) Investigator ’ opinion would : ) warrant exclusion study b ) prevent patient complete study ; 19. limited mental capacity language skill extent simple instruction follow information regard adverse event provide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>failed IFN/RBV treatment</keyword>
</DOC>